Multicenter, single-arm phase II study of nilotinib in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic-phase (CML-CP) patients with low imatinib trough plasma concentrations.

Phase Ii ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Plasma Concentrations ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Trough Plasma ◽

Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1702635 ◽

2000 ◽

Vol 26 (8) ◽

pp. 823-829 ◽

Cited By ~ 16

Author(s):

DW Beelen ◽

R Peceny ◽

A Elmaagacli ◽

H Ottinger ◽

G Kummer ◽

...

Keyword(s):

Phase Ii ◽

Peripheral Blood ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Chronic Phase ◽

Adult Patients ◽

Post Transplant ◽

Peripheral Blood Cd34 ◽

Cd34 Cells

PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY

Value in Health ◽

10.1016/j.jval.2019.09.372 ◽

2019 ◽

Vol 22 ◽

pp. S470

Author(s):

V. Maheshwari ◽

D. Tran ◽

G. Agostoni ◽

K. Filioussi ◽

R. Viana

Keyword(s):

Cost Effectiveness ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Second Line ◽

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia ◽

10.1038/leu.2012.134 ◽

2012 ◽

Vol 26 (10) ◽

pp. 2197-2203 ◽

Cited By ~ 278

Author(s):

R A Larson ◽

A Hochhaus ◽

T P Hughes ◽

R E Clark ◽

G Etienne ◽

...

Keyword(s):

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Newly Diagnosed ◽

Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian Healthcare System

Value in Health ◽

10.1016/j.jval.2017.08.247 ◽

2017 ◽

Vol 20 (9) ◽

pp. A441

Author(s):

N Goyert ◽

D Tran ◽

E Efremova ◽

C Apostopoulos ◽

D Grima

Keyword(s):

Cost Effectiveness ◽

Healthcare System ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Line Treatment ◽

Second Line ◽

Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.6572 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 6572-6572

Author(s):

A. Ovanfors ◽

J. Stephens ◽

S. J. Snedecor ◽

D. Patel ◽

X. Ji ◽

...

Keyword(s):

Cost Effectiveness ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Line Treatment ◽

Newly Diagnosed ◽

First Line ◽

First Line Treatment ◽

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

American Journal of Hematology ◽

10.1002/ajh.23624 ◽

2014 ◽

Vol 89 (3) ◽

pp. 282-287 ◽

Cited By ~ 40

Author(s):

Ohad Benjamini ◽

Theresa Liu Dumlao ◽

Hagop Kantarjian ◽

Susan O'Brien ◽

Guillermo Garcia-Manero ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Phase Ii ◽

Myeloid Leukemia ◽

Phase Ii Trial ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Blast Phase ◽

Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase

Yearbook of Pathology and Laboratory Medicine ◽

10.1016/j.ypat.2012.11.022 ◽

2013 ◽

Vol 2013 ◽

pp. 367-368

Author(s):

H. Signorelli, DO

Keyword(s):

Clinical Trials ◽

Multicenter Study ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Adult Patients ◽

Open Label ◽

Imatinib Resistant ◽

PCN72 Modeling the Survival Loss in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP) Switched from Imatinib Mesylate to a Generic Copy

Value in Health ◽

10.1016/j.jval.2012.08.2112 ◽

2012 ◽

Vol 15 (7) ◽

pp. A422

Author(s):

M. Botteman ◽

M. Magestro ◽

A.F. Alwan

Keyword(s):

Imatinib Mesylate ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Generic Copy ◽

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Leukemia ◽

10.1038/leu.2012.181 ◽

2012 ◽

Vol 27 (1) ◽

pp. 107-112 ◽

Cited By ~ 128

Author(s):

F J Giles ◽

P D le Coutre ◽

J Pinilla-Ibarz ◽

R A Larson ◽

N Gattermann ◽

...

Keyword(s):

Phase Ii ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Chronic Phase ◽

Imatinib Resistant

RETRACTED ARTICLE: Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

Hematology ◽

10.1080/10245332.2018.1444919 ◽

2018 ◽

pp. 1-7

Keyword(s):

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Newly Diagnosed ◽

Retracted Article ◽

Turkish Patients ◽